We have demonstrated that the EMT-activator ZEB1 provides cancer cells not only with aberrant motility, but also with survival traits enabling tumor progression, metastasis and drug resistance. Our aim is to eliminate these aggressive untargetable EMT-state cancer cells, which strikingly show a high sensitivity to ferroptotic cell death. In this project, we want to elucidate the molecular basis of ZEB1 associated ferroptosis sensitivity to exploit it as a novel therapeutic target.
Research projects
D039: EMT specific splicing mediates ferroptosis sensitivity
(FAU Funds)
J101: AI-based support for histopathology evaluation of autoinflammatory and malignant GI diseases
(FAU Funds)
2025
2024
2023
2022
2021
2020
Related Research Fields
Contact: